To the full analysis
Buyback calculator for Vertex Pharmaceuticals
Vertex Pharmaceuticals stock: key metrics
VRTXVertex Pharmaceuticals had an operating margin of 39.4% and a return on invested capital (ROIC) of 29% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 94.4% | −105.9% | −95.6% |
| 2007 | 93.0% | −210.9% | −196.6% |
| 2008 | 91.1% | −263.6% | −262.0% |
| 2009 | 86.1% | −601.1% | −628.7% |
| 2010 | 91.1% | −485.5% | −526.3% |
| 2011 | 94.3% | 8.1% | 2.1% |
| 2012 | 81.7% | 0.2% | −7.0% |
| 2013 | 89.3% | −74.5% | −36.7% |
| 2014 | 89.5% | −119.3% | −127.2% |
| 2015 | 87.8% | −45.4% | −54.1% |
| 2016 | 87.6% | 0.6% | −6.6% |
| 2017 | 88.9% | 5.0% | 10.6% |
| 2018 | 86.6% | 20.8% | 68.8% |
| 2019 | 86.8% | 28.8% | 28.3% |
| 2020 | 88.1% | 46.0% | 43.7% |
| 2021 | 88.1% | 36.7% | 30.9% |
| 2022 | 87.9% | 48.2% | 37.2% |
| 2023 | 87.2% | 38.8% | 36.7% |
| 2024 | 86.1% | −2.1% | −4.9% |
| 2025 | 85.0% | 39.4% | 32.7% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −40.9% | −23.4% | −22.4% |
| 2007 | −100.0% | −55.4% | −65.1% |
| 2008 | −100.0% | −61.6% | −46.9% |
| 2009 | −58.5% | −39.3% | −32.8% |
| 2010 | −100.0% | −35.6% | −43.7% |
| 2011 | 3.8% | 4.8% | 1.3% |
| 2012 | −10.7% | 0.4% | −3.9% |
| 2013 | −32.8% | −33.6% | −19.2% |
| 2014 | −68.7% | −28.0% | −31.6% |
| 2015 | −59.4% | −52.5% | −22.4% |
| 2016 | −9.7% | 1.0% | −3.9% |
| 2017 | 13.0% | 14.9% | 7.4% |
| 2018 | 47.3% | 52.6% | 33.6% |
| 2019 | 19.3% | 42.2% | 14.1% |
| 2020 | 31.2% | 84.3% | 23.1% |
| 2021 | 23.2% | 73.4% | 17.4% |
| 2022 | 23.9% | 89.2% | 18.3% |
| 2023 | 20.6% | 56.5% | 15.9% |
| 2024 | −3.3% | −1.2% | −2.4% |
| 2025 | 21.2% | 29.0% | 15.1% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 8 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.